Zimmer Biomet (ZBH) Expected to Post Quarterly Earnings on Wednesday

Zimmer Biomet (NYSE:ZBH) is anticipated to post its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of $2.01 per share and revenue of $2.1348 billion for the quarter. Investors can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:30 AM ET.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH traded down $1.91 during trading on Tuesday, hitting $95.07. The company had a trading volume of 218,207 shares, compared to its average volume of 2,289,722. The stock has a 50 day simple moving average of $89.07 and a 200 day simple moving average of $89.91. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73. Zimmer Biomet has a 12 month low of $79.12 and a 12 month high of $108.29. The firm has a market capitalization of $18.39 billion, a P/E ratio of 24.74, a price-to-earnings-growth ratio of 2.77 and a beta of 0.45.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, July 31st. Investors of record on Thursday, June 25th were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend was Thursday, June 25th. Zimmer Biomet’s dividend payout ratio is currently 24.94%.

Analyst Ratings Changes

A number of research firms have commented on ZBH. Canaccord Genuity Group set a $83.00 target price on shares of Zimmer Biomet in a research note on Wednesday, April 29th. Citizens Jmp dropped their price target on shares of Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating for the company in a research report on Wednesday, April 29th. Wells Fargo & Company reduced their price objective on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 29th. Citigroup decreased their price objective on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a research report on Thursday, May 28th. Finally, Truist Financial restated a “hold” rating and set a $92.00 target price (down from $98.00) on shares of Zimmer Biomet in a research note on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, twelve have issued a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $102.00.

Insider Transactions at Zimmer Biomet

In related news, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the transaction, the insider directly owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. The trade was a 15.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.28% of the company’s stock.

Institutional Investors Weigh In On Zimmer Biomet

Institutional investors have recently added to or reduced their stakes in the stock. DV Equities LLC bought a new stake in shares of Zimmer Biomet during the fourth quarter valued at approximately $25,000. Gen Wealth Partners Inc bought a new position in shares of Zimmer Biomet during the fourth quarter worth $31,000. Headlands Technologies LLC purchased a new position in Zimmer Biomet during the second quarter valued at $37,000. EFG International AG purchased a new position in Zimmer Biomet during the fourth quarter valued at $55,000. Finally, Mpwm Advisory Solutions LLC bought a new stake in Zimmer Biomet in the 3rd quarter valued at $65,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.